MB BCh BAO, FCICM, MD, FFA RCSI, MSc (Anaes), DIBICM, PG Dip Echo
Martina graduated from the National University of Ireland, Galway in 1997. She was admitted by Fellowship to the College of Anaesthetists of Ireland in 2001 and completed her specialist training in Anaesthesia in Ireland in 2007. During this time she completed a Masters of Medical Science in Anaesthesia. She was awarded a Doctor of Medicine Degree in 2009 for her thesis based on research carried out at NUI Galway from 2004-2006. She moved to Australia in 2008 and was admitted as a Fellow to the College of Intensive Care Medicine in 2009. She has been working as a staff specialist in Intensive Care at Geelong since 2010.
Her areas of interest include Safety and Quality of care delivery, Rapid Response Systems and the Deteriorating Patient, ECMO and Echocardiography. She is a member of the Deteriorating Patient Committee, Antimicrobial Stewardship Committee and Central Venous Catheter Working Group.
Head of ECMO
Martina is the Head of the UHG ICU ECMO service, the 2nd largest adult ECMO program in Victoria.
Latest news:
-
Thursday, August 26, 2021 - 01:57
JAMA BaSICS rate: Slower vs faster fluid challenge in critically ill patients not significantly reduce 90-day mortality. In addition there was a lower use of vasopressors on day 3 in the slower infusion rate group. Adds to SPLIT and SMART trials.
Monday, August 23, 2021 - 13:54NEJM Convalescent plasma RCT for high-risk patients present to ED within 7 days after the onset of symptoms = no difference disease progression
Monday, August 23, 2021 - 12:27NEJM VITT review 237 suspected from 24 million Oxford-Astra Zeneca doses, incidence at least 1:100,000 >50 years, 1:50,000 <50 years, occurs 5-30 days after first dose. Extensive thrombotic sites, cerebral venous thrombosis dominant. Low platelets, increased D-dimer, reduced fibrinogen associated worse outcomes. Overall case fatality rate 23%, highest in patients with both ICH and platelet count below 30,000. No therapeutic options proven effective, although IVIG, corticosteroids, plasma exchange, and non-heparin anticoagulation are used.
Sunday, August 22, 2021 - 19:03JC DOREMI RCT reports no difference in composite primary outcome with milrinone vs dobutamine for cardiogenic shock (49% M vs 54% D, RR, 0.90; 95% CI, 0.69 to 1.19; P=0.47). No difference in secondary outcomes. It was powered to detect a large effect.
Sunday, August 22, 2021 - 11:21REMAP-CAP, ACTIV-4a, and ATTACC harmonised multiplatform, randomized trial 2244 non-ICU patients with COVID- for every 1000 patients, therapeutic anticoagulation vs thromboprophylaxis expected to result in 40 additional patients surviving to hospital discharge without organ support, and 7 major bleeds.